Outcomes of Reinduction With Nadofaragene Firadenovec

Affiliations

¹ Huntsman Cancer Institute, Salt Lake City, Utah.
² Early Career Editor, The Journal of Urology®.
³ Department of Surgery, Division of Urology, University of Utah, Salt Lake City, Utah.
⁴ Mayo Clinic Arizona, Scottsdale, Arizona.
⁵ Department of Urology, University of Southern California, Los Angeles, California.
⁶ Western Section Representative, The Journal of Urology®.
⁷ Saint John's Health Center, Santa Monica, California.
⁸ National Cancer Institute, Bethesda, Maryland.
⁹ Emory University School of Medicine, Atlanta, Georgia.
¹⁰ Chesapeake Urology Associates LLC, Hanover, Maryland.
¹¹ Vanderbilt University Medical Center, Nashville, Tennessee.
¹² The University of Texas Southwestern Medical Center, Dallas, Texas.

Editorial

Bogdana Schmidt et al. J Urol. 2025 Nov.

. 2025 Nov;214(5):472-473.

doi: 10.1097/JU.0000000000004697. Epub 2025 Aug 25.

¹ Huntsman Cancer Institute, Salt Lake City, Utah.
² Early Career Editor, The Journal of Urology®.
³ Department of Surgery, Division of Urology, University of Utah, Salt Lake City, Utah.
⁴ Mayo Clinic Arizona, Scottsdale, Arizona.
⁵ Department of Urology, University of Southern California, Los Angeles, California.
⁶ Western Section Representative, The Journal of Urology®.
⁷ Saint John's Health Center, Santa Monica, California.
⁸ National Cancer Institute, Bethesda, Maryland.
⁹ Emory University School of Medicine, Atlanta, Georgia.
¹⁰ Chesapeake Urology Associates LLC, Hanover, Maryland.
¹¹ Vanderbilt University Medical Center, Nashville, Tennessee.
¹² The University of Texas Southwestern Medical Center, Dallas, Texas.

No abstract available

Keywords: bladder cancer; immuno-oncology; intravesical.

Comment in

Editorial Comment.
Braga LH. Braga LH. J Urol. 2025 Dec;214(6):641. doi: 10.1097/JU.0000000000004741. Epub 2025 Sep 5. J Urol. 2025. PMID: 40910493 No abstract available.